With 41249.0 shares changed hands, the volume of the stock remained heavier than its average volume of 36100.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.6249 whereas the lowest price it dropped to was $0.6. The 52-week range on NBY shows that it touched its highest point at $1.01 and its lowest point at $0.44 during that stretch. It currently has a 1-year price target of $0.85. Beta for the stock currently stands at 0.50.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NBY was up-trending over the past week, with a rise of 2.60%, but this was down by -8.05% over a month. Three-month performance surged to 1.68% while six-month performance fell -10.61%. The stock lost -0.17% in the past year, while it has gained 21.93% so far this year.
Float and Shares Shorts:
At present, 5.82 million NBY shares are outstanding with a float of 5.82 million shares on hand for trading. On 2025-07-31, short shares totaled 34147.0, which was 58.999998 higher than short shares on 1751241600. In addition to Mr. Justin M. Hall Esq., J.D. as the firm’s President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director, Mr. Tommy Law serves as its Controller, Interim CFO & Treasurer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, NBY reported revenue of $0.0 and operating income of -$1891000.0. The EBITDA in the recently reported quarter was -$1926000.0 and diluted EPS was -$0.33.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NBY since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.26 being high and -$3.26 being low. For NBY, this leads to a yearly average estimate of -$3.26. The surprise factor in the prior quarter was -$0.31.
